Please assess the completion status of the following clinical trial:

Trial Title: Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histological confirmed diagnosis cancer~* symptomatic malignant ascites~* EpCAM positive tumor~* EOCG 0-2~* negative pregnancy~Exclusion Criteria:~* acute or chronic infection~* exposure to investigational product, cancer chemo- or radiotherapy within the last 28 days~* previous treatment with mouse monoclonal antibodies~* known or suspected hypersensitivity to Removab or similar antibodies~* inadequate renal function~* inadequate hepatic function (AST, ALt, GTP,\< x ULN; bilirubin \<1.5xULN)~* Platelets \> 80000 cells/mm3; absolute neutrophil count (ANC) \< 1500 cells/mm3~* BMI \< 17~* Patients with reduced nutritional status~* Ileus within the last 30 days~* Brain metastases in cancer history~* Pregnant and nursing women~* history of myocardial infarction, congestive heart failure or relevant cardiac arrhythmia within previous 3 months~* inadequate respiratory function in option of investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 Catumaxomab (Type: ACTIVE_COMPARATOR): Patient received Catumaxomab and paracentesis
- 2: (Type: NO_INTERVENTION): Patient treated by paracentesis alone, but after the second paracentesis the patient is able to cross-over in the Catumaxomab-arm

Based on this trial design, predict the completion outcome and termination type (if applicable).